RYTM vs HALO vs RARE vs FOLD vs ACMR

For growth investors, Rhythm Pharmaceuticals, Inc.

(RYTM) is the stronger pick with 45. 8% revenue growth year-over-year, versus 15. 2% for ACM Research, Inc. (ACMR). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 0x trailing P/E (8. 0x forward), making it the more compelling value choice. Analysts rate Rhythm Pharmaceuticals, Inc. (RYTM) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 25. 0x versus ACM Research, Inc. at 43. 7x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus ACM Research, Inc. 's 0. 87x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Rhythm Pharmaceuticals, Inc.

(RYTM) delivered a total return of +359. 1%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: ACMR returned +31. 0% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus ACM Research, Inc. 's 3. 17β — meaning ACMR is approximately 519% more volatile than HALO relative to the S&P 500. On balance sheet safety, ACM Research, Inc. (ACMR) carries a lower debt/equity ratio of 16% versus 177% for Rhythm Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Rhythm Pharmaceuticals, Inc.

(RYTM) is pulling ahead at 45. 8% versus 15. 2% for ACM Research, Inc. (ACMR). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 51. 2% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, RYTM leads at 100. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — RYTM leads at 89. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus ACM Research, Inc. 's 0. 87x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 0x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 32. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 85. 1% to $48. 36.

In this comparison, ACMR (0.

2% yield) pays a dividend. RYTM, HALO, RARE, FOLD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +559. 7%, ACMR: +31. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RYTM (Healthcare) and HALO (Healthcare) and RARE (Healthcare) and FOLD (Healthcare) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.